Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons.
D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology; D048588:Benzoxazines; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology; D020864:Calcium Channels, N-Type / Q000378:metabolism*; D002186:Cannabinoids / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D063388:Endocannabinoids; D051676:G Protein-Coupled Inwardly-Rectifying Potassium Channels; D019204:GTP-Binding Proteins / Q000378:metabolism*; D005989:Glycerides / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D009025:Morpholines / Q000494:pharmacology; D009281:Naphthalenes / Q000494:pharmacology; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D053284:Polyunsaturated Alkamides; D015221:Potassium Channels / Q000378:metabolism*; D024661:Potassium Channels, Inwardly Rectifying; D051381:Rats; D017208:Rats, Wistar; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists / Q000378:metabolism*
D001095:Arachidonic Acids; D048588:Benzoxazines; D002121:Calcium Channel Blockers; D020864:Calcium Channels, N-Type; D002186:Cannabinoids; D063388:Endocannabinoids; D051676:G Protein-Coupled Inwardly-Rectifying Potassium Channels; D005989:Glycerides; D009025:Morpholines; D009281:Naphthalenes; D053284:Polyunsaturated Alkamides; D015221:Potassium Channels; D024661:Potassium Channels, Inwardly Rectifying; D043884:Receptor, Cannabinoid, CB1; C424442:noladin ether; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; C094503:glyceryl 2-arachidonate; D019204:GTP-Binding Proteins; D002118:Calcium; C078814:anandamide